(UPDATED) There is no difference in in-hospital outcomes or longer-term mortality between patients undergoing revascularization with either a durable-polymer DES or newer technology with a ...

Valued for their ability to safely degrade in the body over time, bioabsorbable materials have had a profound impact on medical device development in recent years. In addition to their widespread use ...

WASHINGTON - A novel study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) presented a safety advantage without compromising efficacy compared to durable ...

Clinical trial establishes non-inferiority of drug-eluting stent with a bioabsorbable polymer compared to traditional drug-eluting stent with durable polymer San Francisco, CA --A clinical trial has ...

To address concerns of late and very late stent thrombosis associated with first generation drug-eluting stent technology, novel approaches are being tested including stents with bioabsorbable ...

CALGARY, Alberta--(BUSINESS WIRE)--Fluid Biomed Inc., a clinical stage medical device company developing lifesaving products for patients suffering from vascular disease, closed an oversubscribed $27 ...

The Absorv™ bioabsorbable products from Zeus can safely exist in the human body for controlled periods of time before they are absorbed without causing any harm or negative interactions. Such products ...

Please provide your email address to receive an email when new articles are posted on . Biotronik announced that a drug-eluting stent system for the treatment of patients with CAD has been approved by ...

Boston Scientific, a global medical technology leader, has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated in the US to examine the ...

The rapidly expanding use of orthopedic implants engineered from bioabsorbable polymers has, in many cases, dramatically improved patient care by eliminating the presence of 'temporary' medical ...

New data from the IDEAL-LM trial found that a biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) was safe and effective compared to a ...

Patients with more complex anatomy showed improved clinical outcomes with Biomatrix Flex including less cardiac death (HR: 0.43; 95% CI: 0.21–0.89; p = 0.02). In addition, low rates of definite stent ...